Ever wondered what side effects come with PARP inhibitors in #prostatecancer? Our new review in Current Opinion in #Urology breaks down their toxicity profile and why close monitoring matters. Nyirády Dr. Péter Marcin Miszczyk Shahrokh F. Shariat Tibor Szarvas tinyurl.com/ym3frddm

Would renaming Gleason Score 6 prostate cancer as non-cancer lead to better outcomes? Listen to our latest podcast with Prof. Scott Eggener Scott Eggener as we explore this important and timely debate.European Association of Urology (EAU) Society of Urologic Oncology European Society of Residents in Urology EAU Young Academics

Honored and proud to be part of such a meaningful contribution! 👏🏼👏🏼

Excited to share our latest paper on ARPI monotherapy in #ProstateCancer Eur Urol Focus EAU YAU Prostate Cancer Working Group Marcin Miszczyk Alexander Giesen Juan Gómez Rivas Axel S. Merseburger steven joniau Giancarlo Marra Nyirády Dr. Péter Giorgio Gandaglia Shahrokh F. Shariat Pawel Rajwa Semmelweis University Urologic Oncology Research MedUni Vienna tinyurl.com/48d4hdtk

A new systematic review & meta-analysis explores the role of androgen receptor pathway inhibitor (ARPI) monotherapy across prostate cancer stages. •⚖️ Similar overall safety to ADT or ARPI+ADT combo •❤️‍🔥 Fewer hot flushes •⚠️ More breast-related side effects (pain &

Prostate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with #ProstateCancer Treated with Androgen Receptor Pathway Inhibitors eu-focus.europeanurology.com/article/S2405-… This meta-analysis of 14 studies including 8,883 patients evaluated the association between

Interesting data! However, we observed similar effect sizes in MAGNITUDE, which ultimately did not translate into an overall survival benefit (euoncology.europeanurology.com/article/S2588-…). Will 'earlier is the better' hold true this time? #prostatecancer

Our first analysis of the Hungarian National Insurance Database 👇👇 In 3,497 mCRPC patients (2013–2023), enzalutamide was associated with longer overall survival vs abiraterone (HR 0.84, p=0.008)! Nyirády Dr. Péter Tibor Szarvas Pawel Rajwa Boris Hadaschik 🔗 tinyurl.com/bdhneu9s

The shorter the better ☝🏼☝🏼

I am extremely grateful for my exceptional mentors: Shahrokh F. Shariat Nyirády Dr. Péter and Pawel Rajwa

Local radiotherapy doesn’t improve OS in mHSPC patients, but significantly prolongs time to ADT resistance. Redefining selection criteria is key to identify those who truly benefit in the era of next-generation imaging and modern systemic therapies. sciencedirect.com/science/articl…

Amazing real-world paper demonstrating the transformative role of PSMA PET in guiding prostate cancer care! PSMA-PET is not only diagnostic—it’s therapeutic too.

Youngest patients suffer the biggest loss from advanced #ProstateCancer ! Men aged 45–60 with metastatic disease lose 12+ years of life — >3× the loss in men aged 61–75. Locally advanced: 2.69 yrs vs 0.37 yrs. Could early detection change the story? tinyurl.com/4c7br477

A clear guidance for #everyone who is into SR/MAs! #methodology #prostatecancer

What a great piece!

Real-world data at its best! It was a great honour and challenge to work on this piece! #prostatecancer Pawel Rajwa

Until today, I wasn’t sure how well his works could translate into other languages - probably well enough to earn a Nobel Prize 😉 Extremely proud and grateful!

Rectal Swab–based Targeted Prophylactic Antibiotics Reduce Infectious Complications After Transrectal Prostate Biopsy sciencedirect.com/science/articl… In this systematic review and meta-analysis of nine randomized controlled trials including 3,002 patients, the use of targeted

Happy 100th birthday Hungarian Urological Society! 🥳🥳🍾🍾 Special thanks to our stellar guest speakers: Arnulf Stenzl on behalf of European Association of Urology (EAU), Shahrokh F. Shariat, Marek Babjuk, Piotr Chłosta, Paolo Gontero, Prof. Babela, Prof. Haas. Nyirády Dr. Péter

Can happen if you don't use ARPI switch as control.